News & Press Releases Swedish

Scandinavian ChemoTech förutspår högre framtida intäkter efter att ha tecknat ett tredje kommersiellt kontrakt i Indien

Avtalet, som är ett hyresavtal, avser en installation på Asirvatham Specialty Hospital i Madurai, ett medelstort privat sjukhus. De beräknade intäkterna för detta avtal, när systemet är fullt implementerat, är minst 50 000 EUR, med en potential att nå över 100 000 EUR per år. Detta belopp är betydligt högre jämfört med prognosen ChemoTech gjorde…

Read more

Scandinavian ChemoTech tecknar distributionsavtal för Chile med Lambertis Corporation SA

ChemoTech har idag tecknat ett distributionsavtal med Lambertis Corporation SA "Lambertis" i Chile, vilket innebär att ChemoTech nu för första gången introducerar IQwave och dess TSE-teknologi till ett land på den sydamerikanska onkologimarknaden.

Read more

Scandinavian ChemoTech AB uppdaterar om försäljning, kliniska och R&D-projekt och framtida milstolpar

Med detta nyhetsbrev vill ChemoTech ge våra olika intressenter en uppdatering om vår kommersialiseringsprocess samt våra kliniska och R&D-projekt för både Human- och Animal Care-divisionerna.

Read more

News & Press Releases English

Scandinavian ChemoTech foresees higher future revenues after signing a third commercial contract in India

The agreement involves a rental installation at Asirvatham Speciality Hospital in Madurai, a medium-sized private hospital. The estimated revenues for this agreement, once the system is fully implemented, is at least EUR 50.000, with a potential to reach over EUR 100.000 per year. This amount is significantly higher compared to the projection per installation made…

Read more

Scandinavian ChemoTech signs distribution agreement for Chile with Lambertis Corporation SA

ChemoTech has today signed a distribution agreement with Lambertis Corporation SA "Lambertis" in Chile, which means that ChemoTech is now going to start the process of introducing the IQwave™ and its TSE technology to the first country in South America.

Read more

Scandinavian ChemoTech AB updates on sales, clinical- and R&D projects and future milestones

With this newsletter, ChemoTech wishes to provide our various stakeholders with an update on our commercialisation process as well as our clinical- and R&D projects for both Human- and Animal Care.

Read more

ChemoTech Videos

2023

Redeye Investor Forum - Company Presentation

Clinical strategy update from Medical Director Dr. Suhail Mufti

Redeye Fight Cancer Day 2023 - ChemoTech

2022

ChemoTech 2022 - Mohan Frick CEO summarises the year (Swedish)

ChemoTech Q2 2022 - Livestream Presentation (in Swedish)

SWECARE at EXPO 2020 DUBAI: "Closing Ceremony"

A conversation with Småbolagspodden

(Audio in Swedish)

I det senaste avsnittet av Småbolagspodden berättar Scandinavian ChemoTechs vd Mohan Frick om hur bolagets unika metod för cancerbehandling, via så kallad tumörspecifik elektroporation, ska hjälpa människor och djur världen över.

Lyssna på hela avsnittet här:
52. ChemoTech – Vill vara en kraft för skonsammare cancervård

2021

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Videos from 2020

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in electroporation forms the starting point for the company’s existing product and R&D projects: The IQwave™ specially designed for our TSE™ – Tumour Specific Electroporation technology which treats a range of various tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.